GlassScriptPhysician profile
Brittany Cook
NPI 1639646961
$2,080.39
in general payments reported to CMS, 2019-2025
23 companies · $464 in 2025
The $464 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $647 · 2022: $354 · 2023: $434 · 2024: $182 · 2025: $464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,080.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,079.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $832.36 | 2021-2025 | |
| Janssen Biotech, INC. | $130.86 | 2021-2024 | Stelara, Simponi, Simponi Aria |
| Eisai INC. | $100.00 | 2021 | |
| Intercept Pharmaceuticals, INC. | $89.76 | 2022-2024 | Ocaliva |
| Daiichi Sankyo INC. | $89.11 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $88.16 | 2022-2025 | Xifaxan |
| Madrigal Pharmaceuticals | $75.16 | 2024-2025 | Rezdiffra, Resmetirom |
| Pfizer INC. | $74.92 | 2023-2024 | |
| Redhill Biopharma INC. | $70.05 | 2021 | |
| Vivus LLC | $69.12 | 2021-2025 | Pancreaze |
| Boston Scientific Corporation | $68.12 | 2021-2025 | Wavewriter Alpha Prime 16 |
| Takeda Pharmaceuticals U.S.A., INC. | $56.29 | 2022-2025 | Eohilia, Entyvio |
| Ipsen Biopharmaceuticals, INC | $53.10 | 2023-2025 | Bylvay, Iqirvo |
| Nestle Healthcare Nutrition INC. | $44.77 | 2021 | |
| Merit Medical Systems INC | $38.72 | 2025 | Endomaxx Stent and Delivery System, Esophyx |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $34.44 | 2025 | Voquezna |
| Lucid Diagnostics INC. | $27.96 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $27.73 | 2024 | Dupixent |
| Gilead Sciences, INC. | $26.76 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.64 | 2023 | Cyltezo |
| Aimmune Therapeutics, INC. | $21.43 | 2025 | Zenpep |
| Organon LLC | $20.13 | 2022 | |
| Braintree Laboratories, INC. | $17.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittany Cook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.